FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078305535> ?p ?o ?g. }

• W2078305535 endingPage "115" @default.
• W2078305535 startingPage "113" @default.
• W2078305535 abstract "ImmunotherapyVol. 5, No. 2 EditorialEffects of TNF-α inhibitors upon the mechanisms of action of VEGFGiuseppe Murdaca, Francesca Spanò, Maurizio Miglino & Francesco PuppoGiuseppe Murdaca* Author for correspondenceDepartment of Internal Medicine, Clinical Immunology Unit, University of Genova, Viale Benedetto XV, n. 6, 16132 Genova, Italy. Search for more papers by this authorEmail the corresponding author at giuseppe.murdaca@unige.it, Francesca SpanòDepartment of Internal Medicine, Clinical Immunology Unit, University of Genova, Viale Benedetto XV, n. 6, 16132 Genova, ItalySearch for more papers by this author, Maurizio MiglinoDepartment of Internal Medicine, Clinical Haematological Unit, University of Genova, Viale Benedetto XV, n. 6, 16132 Genova, ItalySearch for more papers by this author & Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genova, Viale Benedetto XV, n. 6, 16132 Genova, ItalySearch for more papers by this authorPublished Online:15 Feb 2013https://doi.org/10.2217/imt.12.151AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: TNF-α inhibitorVEGFReferences1 Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf.11(1),1–5 (2012).Crossref, Medline, CAS, Google Scholar2 Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun. Rev.11(1),56–60 (2011).Crossref, Medline, Google Scholar3 Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc.)47(4),277–288 (2011).Crossref, Medline, CAS, Google Scholar4 Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int. J. Immunopathol. Pharmacol.22(3),557–565 (2009).Crossref, Medline, CAS, Google Scholar5 Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am. J. Clin. Dermatol.11(6),437–439 (2010).Crossref, Medline, Google Scholar6 Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol.38(6),439–444 (2009).Crossref, Medline, CAS, Google Scholar7 Cañete JD, Pablos JL, Sanmartí R et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum.50(5),1636–1641 (2004).Crossref, Medline, CAS, Google Scholar8 Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res. Ther.10(5),R125 (2008).Crossref, Medline, Google Scholar9 Avramidis G, Krüger-Krasagakis S, Krasagakis K, Fragiadaki I, Kokolakis G, Tosca A. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br. J. Dermatol.163(5),928–934 (2010).Crossref, Medline, CAS, Google Scholar10 Campanati A, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Br. J. Dermatol.167(1),68–76 (2012).Crossref, Medline, CAS, Google Scholar11 Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum. Immunol.69(8),510–512 (2008).Crossref, Medline, CAS, Google Scholar12 Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy63(7),945–946 (2008).Crossref, Medline, CAS, Google Scholar13 Kanbe K, Inoue K, Inoue Y, Suzuki Y. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. Clin. Rheumatol.27(6),777–781 (2008).Crossref, Medline, Google Scholar14 Strunk J, Bundke E, Lange U. Anti-TNF-alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol. Int.26(3),252–256 (2006).Crossref, Medline, CAS, Google Scholar15 Visvanathan S, van der Heijde D, Deodhar A et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann. Rheum. Dis68(2),175–182 (2009).Crossref, Medline, CAS, Google Scholar16 Calleja S, Cordero-Coma M, Rodriguez E, Llorente M, Franco M, Ruiz de Morales JG. Adalimumab specifically induces CD3+ CD4+ CD25(high) Foxp3+ CD127- T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye26,468–477 (2012).Crossref, Medline, CAS, Google Scholar17 Rutella S, Fiorino G, Vetrano S et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn’s disease. Am. J. Gastroenterol.106(4),762–770 (2011).Crossref, Medline, CAS, Google Scholar18 Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J. Interferon Cytokine Res.32(6),277–279 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited BySustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma31 July 2023 | Pharmaceutics, Vol. 15, No. 8Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea20 June 2023 | Frontiers in Medicine, Vol. 10Clinical and Translational Significance of Basophils in Patients with Cancer27 January 2022 | Cells, Vol. 11, No. 3Update upon the infection risk in patients receiving TNF alpha inhibitors27 February 2019 | Expert Opinion on Drug Safety, Vol. 18, No. 3Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis24 August 2017 | Modern Rheumatology, Vol. 28, No. 3Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?11 November 2015 | Expert Opinion on Drug Safety, Vol. 15, No. 1Infection risk associated with anti-TNF-α agents: a review29 January 2015 | Expert Opinion on Drug Safety, Vol. 14, No. 4Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab TreatmentInternational Journal of Rheumatology, Vol. 2015Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy10 October 2014 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 10, No. 12Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?8 November 2014 | Drug Development Research, Vol. 75Efficacy and safety of etanercept in chronic immune-mediated disease22 March 2014 | Expert Opinion on Drug Safety, Vol. 13, No. 5Potential use of TNF-α inhibitors in systemic sclerosisGiuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla & Francesco Puppo24 April 2014 | Immunotherapy, Vol. 6, No. 3Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety3 January 2014 | Expert Opinion on Drug Safety, Vol. 13, No. 3Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis29 July 2013 | Expert Opinion on Drug Safety, Vol. 12, No. 6Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors15 November 2013 | Redox Report, Vol. 18, No. 3 Vol. 5, No. 2 STAY CONNECTED Metrics Downloaded 147 times History Published online 15 February 2013 Published in print February 2013 Information© Future Medicine LtdKeywordsTNF-α inhibitorVEGFFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2078305535 created "2016-06-24" @default.
• W2078305535 creator A5005600149 @default.
• W2078305535 creator A5045664956 @default.
• W2078305535 creator A5048224601 @default.
• W2078305535 creator A5052016973 @default.
• W2078305535 date "2013-02-01" @default.
• W2078305535 modified "2023-09-23" @default.
• W2078305535 title "Effects of TNF-α inhibitors upon the mechanisms of action of VEGF" @default.
• W2078305535 cites W1601110874 @default.
• W2078305535 cites W1895554049 @default.
• W2078305535 cites W1964194915 @default.
• W2078305535 cites W1977385433 @default.
• W2078305535 cites W1982225076 @default.
• W2078305535 cites W1992600778 @default.
• W2078305535 cites W1996879287 @default.
• W2078305535 cites W2016298926 @default.
• W2078305535 cites W2026524651 @default.
• W2078305535 cites W2027555348 @default.
• W2078305535 cites W2035856885 @default.
• W2078305535 cites W2037192832 @default.
• W2078305535 cites W2089068941 @default.
• W2078305535 cites W2096287192 @default.
• W2078305535 cites W2097668348 @default.
• W2078305535 cites W2111840934 @default.
• W2078305535 cites W2159713247 @default.
• W2078305535 cites W2198301900 @default.
• W2078305535 doi "https://doi.org/10.2217/imt.12.151" @default.
• W2078305535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23413901" @default.
• W2078305535 hasPublicationYear "2013" @default.
• W2078305535 type Work @default.
• W2078305535 sameAs 2078305535 @default.
• W2078305535 citedByCount "23" @default.
• W2078305535 countsByYear W20783055352013 @default.
• W2078305535 countsByYear W20783055352014 @default.
• W2078305535 countsByYear W20783055352015 @default.
• W2078305535 countsByYear W20783055352017 @default.
• W2078305535 countsByYear W20783055352019 @default.
• W2078305535 countsByYear W20783055352020 @default.
• W2078305535 countsByYear W20783055352022 @default.
• W2078305535 countsByYear W20783055352023 @default.
• W2078305535 crossrefType "journal-article" @default.
• W2078305535 hasAuthorship W2078305535A5005600149 @default.
• W2078305535 hasAuthorship W2078305535A5045664956 @default.
• W2078305535 hasAuthorship W2078305535A5048224601 @default.
• W2078305535 hasAuthorship W2078305535A5052016973 @default.
• W2078305535 hasConcept C121332964 @default.
• W2078305535 hasConcept C167734588 @default.
• W2078305535 hasConcept C17991360 @default.
• W2078305535 hasConcept C185592680 @default.
• W2078305535 hasConcept C202751555 @default.
• W2078305535 hasConcept C203014093 @default.
• W2078305535 hasConcept C2776120743 @default.
• W2078305535 hasConcept C2780791683 @default.
• W2078305535 hasConcept C502942594 @default.
• W2078305535 hasConcept C55493867 @default.
• W2078305535 hasConcept C62520636 @default.
• W2078305535 hasConcept C70721500 @default.
• W2078305535 hasConcept C71924100 @default.
• W2078305535 hasConcept C86803240 @default.
• W2078305535 hasConcept C98274493 @default.
• W2078305535 hasConceptScore W2078305535C121332964 @default.
• W2078305535 hasConceptScore W2078305535C167734588 @default.
• W2078305535 hasConceptScore W2078305535C17991360 @default.
• W2078305535 hasConceptScore W2078305535C185592680 @default.
• W2078305535 hasConceptScore W2078305535C202751555 @default.
• W2078305535 hasConceptScore W2078305535C203014093 @default.
• W2078305535 hasConceptScore W2078305535C2776120743 @default.
• W2078305535 hasConceptScore W2078305535C2780791683 @default.
• W2078305535 hasConceptScore W2078305535C502942594 @default.
• W2078305535 hasConceptScore W2078305535C55493867 @default.
• W2078305535 hasConceptScore W2078305535C62520636 @default.
• W2078305535 hasConceptScore W2078305535C70721500 @default.
• W2078305535 hasConceptScore W2078305535C71924100 @default.
• W2078305535 hasConceptScore W2078305535C86803240 @default.
• W2078305535 hasConceptScore W2078305535C98274493 @default.
• W2078305535 hasIssue "2" @default.
• W2078305535 hasLocation W20783055351 @default.
• W2078305535 hasLocation W20783055352 @default.
• W2078305535 hasOpenAccess W2078305535 @default.
• W2078305535 hasPrimaryLocation W20783055351 @default.
• W2078305535 hasRelatedWork W2046005021 @default.
• W2078305535 hasRelatedWork W2350762959 @default.
• W2078305535 hasRelatedWork W2410821956 @default.
• W2078305535 hasRelatedWork W2411217839 @default.
• W2078305535 hasRelatedWork W2417768781 @default.
• W2078305535 hasRelatedWork W2437264929 @default.
• W2078305535 hasRelatedWork W2748952813 @default.
• W2078305535 hasRelatedWork W2779880513 @default.
• W2078305535 hasRelatedWork W2810949818 @default.
• W2078305535 hasRelatedWork W2899084033 @default.
• W2078305535 hasVolume "5" @default.
• W2078305535 isParatext "false" @default.
• W2078305535 isRetracted "false" @default.
• W2078305535 magId "2078305535" @default.
• W2078305535 workType "article" @default.